Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests
Open Access
- 20 October 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 56 (6), 1047-1052
- https://doi.org/10.1093/jac/dki362
Abstract
Objectives: To evaluate bactericidal activity of PPI-0903M and in vitro testing parameters for this compound. Methods: A total of 110 strains were tested to determine MIC and MBC values of PPI-0903M. MIC values were determined by reference broth microdilution whereas MBC was assessed by plating the broth from the MIC well and from those wells above the MIC for each organism onto appropriate drug-free growth media. Seventeen strains were tested by the kill-curve methodology to again evaluate the bactericidal activity of PPI-0903M. Broth microdilution results for 15 strains (in triplicate) were compared with the standard, reference method after modifying several testing parameters. Optimal disc content was assessed by testing seven reference strains with five PPI-0903M disc concentrations (5, 10, 30, 50 and 100 µg). Results: PPI-0903MMBC/MIC ratios were ≤4 in 90% of strains tested. Kill-curve studies showed >99.9% killing at concentrations ≤4× MIC within 8 to 24 h against staphylococci and Enterobacteriaceae tested. PPI-0903M MIC results were rarely influenced by the test or medium changes evaluated [high inoculum, low calcium or reduced pH (5.0)]. Human serum had no effect on in vitro antimicrobial activity of PPI-0903M. The 10 µg disc content would be recommended for optimal correlation of MIC breakpoints of ≤1–4 mg/L. Conclusions: PPI-0903M was generally bactericidal against tested species, and the MIC results were stable across numerous susceptibility test condition changes.Keywords
This publication has 7 references indexed in Scilit:
- Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical StrainsAntimicrobial Agents and Chemotherapy, 2005
- In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599Journal of Infection and Chemotherapy, 2004
- In Vitro Activities of the Novel Cephalosporin LB 11058 against Multidrug-Resistant Staphylococci and StreptococciAntimicrobial Agents and Chemotherapy, 2004
- TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological propertiesBioorganic & Medicinal Chemistry, 2003
- In Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant StaphylococciAntimicrobial Agents and Chemotherapy, 2003
- In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococciJournal of Antimicrobial Chemotherapy, 2002
- In Vitro Activities of RWJ-54428 (MC-02,479) against Multiresistant Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2001